Cargando…
LB-9. Development of a SARS-CoV2 vaccine, ChAdOx1 nCoV19: immunogenicity and safety in older adults
BACKGROUND: The pandemic of SARS-CoV2 has led to a huge impact on population health, resilience of health systems and economies. While social distancing measures have been shown to slow spread, the end of the pandemic will only be achieved with sufficient population immunity in those at greatest ris...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776656/ http://dx.doi.org/10.1093/ofid/ofaa515.1906 |
Ejemplares similares
-
LB9. Longitudinal antibody dynamics in children infected with SARS-CoV-2 through 6 months post-infection
por: Gentles, Lauren E, et al.
Publicado: (2021) -
Immunogenicity of the ChAdOx1 nCoV-19 vaccine in patients with hematologic malignancies
por: Thookhamme, Chayapa, et al.
Publicado: (2023) -
LB7. Ad26.COV2.S-Elicted Neutralizing Activities Against SARS-CoV-2 Variants of Concern in Phase 1/2a and Phase 3 Clinical Trials
por: Le Gars, Mathieu, et al.
Publicado: (2021) -
LB10. Impact of SARS-CoV-2 Delta Variant on the Spectrum of Pediatric COVID-19 Disease in Arkansas
por: Romero, Jose R, et al.
Publicado: (2021) -
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
por: Schmidt, Tina, et al.
Publicado: (2021)